Alembic Pharmaceuticals Limited announced during the first half of the trading session (at around 10 am to be specific) that it has received tentative approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Palbociclib capsules, 75 mg, 100 mg, and 125 mg.